IBL is an abbreviation with several different meanings depending on the field. The most common uses refer to the International Brain Laboratory, a major neuroscience research collaboration, and immunoblastic lymphadenopathy, an outdated medical term now replaced by a more specific cancer diagnosis. Here’s what each one means and why it matters.
International Brain Laboratory
The International Brain Laboratory is a large-scale research collaboration that brings together experimental and theoretical neuroscience teams from around the world. Its central goal is ambitious: to build a unified, brain-wide theory of how the brain produces complex behavior, mapped down to the level of individual neurons.
The IBL focuses on decision-making. Specifically, its member labs all study the same standardized task in mice. Head-fixed mice turn a small steering wheel to indicate whether a visual stimulus appears to their left or right, earning a water reward for correct answers. By having every lab run the identical task, the IBL can combine data from dozens of experiments into one enormous dataset, something no single lab could generate alone.
To record brain activity during this task, the collaboration uses three complementary techniques. Neuropixels probes capture the firing of individual neurons with millisecond precision across many brain areas simultaneously. Two-photon mesoscopes image large swaths of the cortex. And photometry and microendoscopy track the activity of four major chemical signaling systems: serotonin, dopamine, norepinephrine, and acetylcholine. All of this data flows into a single shared database, where computational scientists develop and test theories about how different brain regions coordinate during a decision.
The project exists because decision-making has proven stubbornly difficult to study. No single brain region controls it. Instead, it involves coordinated activity across many structures, and traditional single-lab experiments can only record from a fraction of them at a time. The IBL’s approach of combining standardized behavior with dense, brain-wide recordings aims to solve that problem by sheer scale and coordination.
Immunoblastic Lymphadenopathy
In medicine, IBL once stood for immunoblastic lymphadenopathy, a rare disorder first described in the 1970s. It was characterized by widespread swollen lymph nodes, an enlarged liver and spleen, skin rashes, anemia, and abnormally high levels of immune proteins in the blood. Some patients also developed joint inflammation that mimicked autoimmune disease.
The term is no longer used as a diagnosis. What doctors in the 1970s called immunoblastic lymphadenopathy (or its close relative, angioimmunoblastic lymphadenopathy with dysproteinemia) is now recognized as angioimmunoblastic T-cell lymphoma, or AITL. The reclassification happened as better tools revealed that these cases were actually a form of cancer, not simply an overactive immune response. AITL is now classified under the broader category of nodal T-cell lymphomas with a follicular T helper cell phenotype.
What AITL Looks Like Today
AITL is an uncommon and aggressive subtype of peripheral T-cell lymphoma. Its symptoms overlap heavily with autoimmune conditions, which can make diagnosis tricky. Patients typically present with swollen lymph nodes throughout the body, fever, skin rashes (often appearing as raised red spots or hives), and constitutional symptoms like fatigue and weight loss. Because of this overlap, AITL is sometimes initially mistaken for an autoimmune disease.
Diagnosis relies on examining lymph node tissue under a microscope, where pathologists look for a characteristic pattern: the normal architecture of the lymph node is replaced by an infiltrate of various immune cells concentrated in specific zones. Flow cytometry, a technique that identifies cell types by their surface markers, can provide an additional diagnostic clue by detecting an unusual population of cells.
Treatment and Outlook
The standard first-line treatment for AITL is combination chemotherapy. According to 2025 guidelines from the National Comprehensive Cancer Network, several chemotherapy combinations are used, and clinical trial participation is considered a preferred option at every stage of treatment. If the cancer returns after initial therapy, several targeted drugs are available as second-line options.
Despite advances in understanding the biology of AITL and the development of newer therapies, the prognosis remains poor. This is an area of active clinical research, and enrollment in clinical trials is consistently recommended for eligible patients.
IBL International
IBL International, short for Immuno-Biological Laboratories, is a diagnostic company that manufactures laboratory test kits. Their products include ELISA-based assays, which are a common type of lab test used to measure specific substances in blood samples. One example is their Total IgE ELISA kit, which measures immunoglobulin E levels to help evaluate patients with suspected allergic conditions like asthma, eczema, hives, and certain parasitic infections. The company primarily serves clinical laboratories and research institutions rather than consumers directly.